SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using 3D bioprinting technology, today announced the hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development. Dr. Tyree has more than 20 years of management and R&D experience in the drug discovery industry in a variety of therapeutic areas at Ligand Pharmaceuticals, TorreyPines Therapeutics (previously Neurogenetics) and most recently served as SVP, Strategic Planning at HUYABIO International.
"Curtis will bring important strategic and dealmaking value to Organovo," said Keith Murphy, executive chairman of Organovo. "His experience in advancing drug development programs, including extensive in-licensing and out-licensing and collaboration with pharmaceutical companies will be extremely valuable to us as we move forward on our plan to leverage 3D intestinal tissues for ulcerative colitis and Crohn’s disease therapies.” Organovo expects to have pipeline opportunities for both in and out-licensing, especially in its first therapeutic area of inflammatory bowel disease (IBD).
"Organovo has the technological expertise, scientific insight and talent base to enable advance of both novel targets and therapeutics in important disease areas," said Dr. Tyree. "I look forward to developing both inward and outward facing partnerships to accelerate the development of novel therapies. I also appreciate the opportunity to assist the management team in developing and realizing the corporate vision."
Organovo is an early-stage biotechnology company that is developing and utilizing highly customized 3D human tissues as dynamic models of healthy and diseased human biology for drug development. The company’s proprietary technology is being used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Organovo’s advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs for selected therapeutic areas.
Forward Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 15, 2021, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 14, 2022. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
Amato and Partners, LLC
Investor Relations Counsel
Source: Organovo, Inc.